<?xml version="1.0" encoding="UTF-8"?>
<ref id="B81">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jacobson</surname>
    <given-names>J. M.</given-names>
   </name>
   <name>
    <surname>Lowy</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Fletcher</surname>
    <given-names>C. V.</given-names>
   </name>
   <name>
    <surname>O’Neill</surname>
    <given-names>T. J.</given-names>
   </name>
   <name>
    <surname>Tran</surname>
    <given-names>D. N.</given-names>
   </name>
   <name>
    <surname>Ketas</surname>
    <given-names>T. J.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2000</year>). 
  <article-title>Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.</article-title>
  <source>
   <italic>J. Infect. Dis.</italic>
  </source>
  <volume>182</volume>
  <fpage>326</fpage>–
  <lpage>329</lpage>. 
  <pub-id pub-id-type="doi">10.1086/315698</pub-id>
  <pub-id pub-id-type="pmid">10882617</pub-id>
 </mixed-citation>
</ref>
